Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
RGLS Regulus Therapeutics Inc. daily Stock Chart
RGLS [NASD]
Regulus Therapeutics Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-2.11 Insider Own13.20% Shs Outstand8.80M Perf Week6.92%
Market Cap8.70M Forward P/E- EPS next Y-4.80 Insider Trans137.98% Shs Float6.82M Perf Month-13.25%
Income-18.30M PEG- EPS next Q-0.92 Inst Own33.60% Short Float3.59% Perf Quarter-31.79%
Sales0.07M P/S120.88 EPS this Y69.40% Inst Trans-7.85% Short Ratio1.04 Perf Half Y-67.69%
Book/sh0.18 P/B5.49 EPS next Y-492.60% ROA-97.60% Target Price3.17 Perf Year-93.46%
Cash/sh2.33 P/C0.42 EPS next 5Y39.60% ROE-311.50% 52W Range0.80 - 15.60 Perf YTD6.28%
Dividend- P/FCF- EPS past 5Y25.90% ROI- 52W High-93.66% Beta2.14
Dividend %- Quick Ratio1.00 Sales past 5Y- Gross Margin- 52W Low23.63% ATR0.08
Employees63 Current Ratio1.00 Sales Q/Q0.00% Oper. Margin- RSI (14)45.81 Volatility9.52% 7.42%
OptionableYes Debt/Eq11.94 EPS Q/Q44.00% Profit Margin- Rel Volume0.53 Prev Close0.99
ShortableYes LT Debt/Eq0.00 EarningsMar 06 AMC Payout- Avg Volume235.45K Price0.99
Recom3.00 SMA202.25% SMA50-11.91% SMA200-72.05% Volume123,613 Change-0.10%
Mar-28-18Initiated B. Riley FBR, Inc. Neutral $1
Jan-05-18Initiated Leerink Partners Outperform $2
Jun-13-17Reiterated Chardan Capital Markets Buy $5 → $2.50
Mar-06-17Reiterated Wedbush Outperform $8 → $6
Jan-30-17Downgrade Wells Fargo Outperform → Market Perform
Jan-30-17Downgrade Needham Buy → Hold
Dec-07-16Reiterated Chardan Capital Markets Buy $12 → $5
Nov-02-16Reiterated Needham Buy $10 → $9
Jul-25-16Reiterated Chardan Capital Markets Buy $14.50 → $12
Jun-28-16Reiterated Needham Buy $25 → $10
Jun-28-16Reiterated FBR Capital Outperform $30 → $9
Jun-28-16Reiterated Chardan Capital Markets Buy $20 → $13.50
Jun-07-16Reiterated Chardan Capital Markets Buy $15 → $20
Apr-13-16Initiated Chardan Capital Markets Buy $15
Dec-04-15Initiated Wells Fargo Outperform
Jun-09-15Initiated Guggenheim Buy
Apr-21-15Resumed FBR Capital Outperform $30
Nov-24-14Initiated Deutsche Bank Buy $30
Aug-07-14Reiterated FBR Capital Outperform $14 → $15
Aug-14-13Reiterated Needham Buy $8 → $12
Jan-07-19 08:00AM  Regulus Announces Clinical Candidate Nomination for the Treatment of Glioblastoma Multiforme PR Newswire
Jan-04-19 04:05PM  Regulus Announces Preliminary Results of Planned Interim Data Analysis of RGLS4326 in New Mouse Chronic Toxicity Study PR Newswire +11.11%
Dec-20-18 09:56AM  Need To Know: Regulus Therapeutics Inc. (NASDAQ:RGLS) Insiders Have Been Buying Shares Simply Wall St.
Nov-28-18 07:35AM  Research Report Identifies Advanced Energy Industries, Altair Engineering, Rambus, Regulus Therapeutics, NN, and Halcon Resources with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +6.00%
Nov-19-18 08:00AM  Regulus Presents Preclinical Survival Data Highlighting Potential of Novel Treatment for Glioblastoma Multiforme PR Newswire
Nov-08-18 06:40PM  Regulus (RGLS) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:38PM  Regulus: 3Q Earnings Snapshot Associated Press
04:05PM  Regulus Reports Third Quarter 2018 Financial Results and Recent Updates PR Newswire
Nov-06-18 07:30AM  Regulus Announces Successful Restructuring of Sanofi Collaboration PR Newswire +6.38%
Oct-25-18 04:05PM  Regulus to Present Data from ATHENA, a Global Natural History of Disease Study for Alport Syndrome, at ASN's Kidney Week 2018 PR Newswire
Oct-23-18 11:30AM  3 Healthcare Stocks To Watch On Tuesday ACCESSWIRE +15.85%
08:35AM  The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares Benzinga
Oct-22-18 04:05PM  Regulus to Present Preclinical Data Supporting RGLS4326 as a Novel Therapeutic in Development for Autosomal Dominant Polycystic Kidney Disease at ASN's Kidney Week 2018 PR Newswire
Oct-18-18 04:05PM  Regulus Regains Compliance with NASDAQ Listing Requirements PR Newswire
Oct-17-18 07:45AM  Research Report Identifies Oxford Immunotec Global, Ascena Retail Group, Groupon, Epizyme, Regulus Therapeutics, and B Communications with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-04-18 08:05AM  Regulus Therapeutics Announces Reverse Stock Split PR Newswire -7.54%
Oct-02-18 04:05PM  Regulus to Participate in Fireside Chat at the Chardan Genetic Medicines Conference PR Newswire -6.05%
Sep-27-18 04:05PM  Regulus to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire
Sep-26-18 04:05PM  Regulus Provides Pipeline Updates PR Newswire
Sep-19-18 02:22PM  Do You Know Who Else Invests In Regulus Therapeutics Inc (NASDAQ:RGLS)? Simply Wall St.
Aug-23-18 12:50PM  These Biotech Stocks Are Moving Higher in August ACCESSWIRE
Aug-09-18 06:10PM  Regulus (RGLS) Reports Q2 Loss, Misses Revenue Estimates Zacks -9.42%
05:05PM  Regulus: 2Q Earnings Snapshot Associated Press
04:05PM  Regulus Reports Second Quarter 2018 Financial Results and Recent Updates PR Newswire
Jul-09-18 09:13AM  Regulus Stock Plunges on Cash Concerns Despite Restructuring Zacks
Jul-05-18 05:00PM  Regulus Announces Strategic Update and Corporate Restructuring PR Newswire
07:35AM  Free Technical Reports on 22nd Century Group and Three Additional Biotech Equities ACCESSWIRE
Jul-03-18 12:38PM  Gaithersburg biotech raising $1M to stop cancer tumors in their tracks American City Business Journals
Jun-12-18 07:45AM  New Research: Key Drivers of Growth for CNA Financial, AutoNation, Hess, Infinity Pharmaceuticals, Regulus Therapeutics, and Weyerhaeuser Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
May-17-18 07:40AM  Report: Developing Opportunities within Regulus Therapeutics, Airgain, Michael Kors, Heritage Insurance, CDK Global, and MedEquities Realty Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
May-10-18 11:46PM  Edited Transcript of RGLS earnings conference call or presentation 10-May-18 9:00pm GMT Thomson Reuters StreetEvents
05:08PM  Regulus: 1Q Earnings Snapshot Associated Press
04:10PM  Regulus Reports First Quarter 2018 Financial Results and Pipeline Progress PR Newswire
May-03-18 04:15PM  Regulus to Provide First Quarter 2018 Financial Results on May 10, 2018 PR Newswire
May-01-18 08:30AM  Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD PR Newswire
Apr-17-18 04:10PM  Kathryn J. Collier Joins Regulus Board of Directors PR Newswire
Mar-20-18 04:15PM  Regulus to Present at the Needham Healthcare Conference PR Newswire
Mar-09-18 12:11AM  Edited Transcript of RGLS earnings conference call or presentation 7-Mar-18 10:00pm GMT Thomson Reuters StreetEvents +12.18%
Mar-07-18 04:31PM  Regulus reports 4Q loss Associated Press
04:10PM  Regulus Reports Fourth Quarter and Year-end 2017 Financial Results and Pipeline Update PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
06:35AM  Was Regulus Therapeutics Incs (NASDAQ:RGLS) Earnings Decline A Part Of Broader Industry Downturn? Simply Wall St.
Mar-05-18 07:01PM  Regulus to Present at the Cowen and Company 38th Annual Health Care Conference PR Newswire
Mar-02-18 08:00AM  New Research: Key Drivers of Growth for New Media Investment Group, Perficient, Strayer Education, Regulus Therapeutics, Kelly Services, and Insys Therapeutics Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire +9.26%
Feb-28-18 04:15PM  Regulus to Provide Fourth Quarter and Year-end 2017 Financial Results on March 7, 2018 PR Newswire -5.13%
Feb-22-18 02:23AM  WuXi STA and Regulus Announce microRNA Development and Manufacturing Collaboration PR Newswire
Feb-08-18 04:15PM  Regulus to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference PR Newswire
Jan-05-18 08:00AM  Analysis: Positioning to Benefit within Churchill Downs, Airgain, Fortune Brands Home & Security, Kemper, Perficient, and Regulus Therapeutics Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire +5.08%
Dec-19-17 08:30AM  Regulus Announces First-in-Human Dosing for Phase I Study of RGLS4326 for the Treatment of Autosomal Dominant Polycystic Kidney Disease PR Newswire
Nov-13-17 06:10PM  Edited Transcript of RGLS earnings conference call or presentation 7-Nov-17 10:00pm GMT Thomson Reuters StreetEvents
Nov-07-17 06:36PM  Regulus reports 3Q loss Associated Press
04:10PM  Regulus Reports Third Quarter 2017 Financial Results and Recent Events PR Newswire
01:00PM  Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Oct-31-17 04:15PM  Regulus to Provide Third Quarter 2017 Financial Results on November 7, 2017 PR Newswire -7.41%
Oct-03-17 08:53AM  Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session Zacks +6.06%
Aug-30-17 04:15PM  Regulus to Present at the 2017 Wells Fargo Healthcare Conference PR Newswire
Aug-25-17 08:35AM  Are Options Traders Betting on a Big Move in Regulus Therapeutics (RGLS) Stock? Zacks -5.88%
Aug-13-17 12:35PM  Edited Transcript of RGLS earnings conference call or presentation 1-Aug-17 9:00pm GMT Thomson Reuters StreetEvents
Aug-08-17 05:00PM  Regulus to Present at the 2017 Wedbush PacGrow Healthcare Conference PR Newswire
Aug-01-17 09:40PM  Regulus reports 2Q loss Associated Press
04:10PM  Regulus Reports Second Quarter 2017 Financial Results and Recent Events PR Newswire
12:15PM  Investor Network: Regulus Therapeutics Inc. to Host Earnings Call ACCESSWIRE
Jul-25-17 09:15PM  Regulus Therapeutics Inc (RGLS) President and CEO Joseph P Hagan Bought $200,000 of Shares GuruFocus.com
04:05PM  Regulus Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire
08:30AM  Regulus to Provide Second Quarter 2017 Financial Results on August 1, 2017 PR Newswire
Jul-19-17 09:45PM  Regulus Announces Pricing of Public Offering of Common Stock PR Newswire
04:01PM  Regulus Announces Commencement of Public Offering of Common Stock PR Newswire
Jun-13-17 02:24PM  Chardan Capital Slashed Price Target on Regulus Therapeutics Inc (RGLS) Following Program Discontinuations SmarterAnalyst
01:12PM  Regulus, AstraZeneca Cut Ties on Liver Disease Treatment, Shares Dip TheStreet.com
08:30AM  Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer PR Newswire
Jun-12-17 07:00AM  Regulus Announces Pipeline Updates and Advancements PR Newswire -16.07%
Jun-08-17 08:00AM  Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics PR Newswire
Jun-01-17 04:15PM  Pascale Witz Joins Regulus Board of Directors PR Newswire
May-17-17 07:05AM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents
May-11-17 04:30PM  Edited Transcript of RGLS earnings conference call or presentation 4-May-17 9:00pm GMT Thomson Reuters StreetEvents -6.06%
May-08-17 08:00AM  Q1 Losses Couldn't Drag Regulus or Corvus Pharmaceuticals Down Accesswire -5.56%
May-05-17 05:03AM  Regulus reports 1Q loss Associated Press +5.88%
May-04-17 04:30PM  Regulus Reports First Quarter 2017 Financial Results and Corporate Restructuring PR Newswire
Apr-27-17 04:10PM  Regulus to Provide First Quarter 2017 Financial Results on May 4, 2017 PR Newswire
Mar-31-17 12:46PM  DEADLINE APRIL 3: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
12:16PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing in Regulus Therapeutics, Inc. to Contact the Firm Before Imminent Lead Plaintiff Deadline Accesswire
11:51AM  DEADLINE MONDAY: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
11:21AM  RGLS DEADLINE ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Regulus Therapeutics Inc. and a Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
09:38AM  DEADLINE ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
08:58AM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline PR Newswire
Mar-30-17 04:47PM  DEADLINE APPROACHING: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Reminds Investors with Losses to Contact the Firm GlobeNewswire
01:35PM  SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Regulus Therapeutics, Inc. To Contact The Firm Before Imminent Lead Plaintiff Deadline GlobeNewswire
11:35AM  IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm Business Wire
10:10AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) & Lead Plaintiff Deadline - April 3, 2017 GlobeNewswire
Mar-28-17 03:18PM  IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire -11.76%
12:36PM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. -- Lead Plaintiff Deadline of April 3, 2017 GlobeNewswire
08:30AM  Regulus to Present at the 16th Annual Needham Healthcare Conference PR Newswire
Mar-27-17 06:05PM  SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Regulus Therapeutics Inc. and Encourages Investors With Losses to Contact the Firm Business Wire +21.43%
09:30AM  Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Accesswire
Mar-24-17 11:50AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Accesswire +12.00%
11:28AM  INVESTOR NOTICE: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
10:29AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Regulus Therapeutics Inc. (RGLS) and Lead Plaintiff Deadline - April 3, 2017 Accesswire
Mar-22-17 10:54AM  INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire
09:46AM  INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Commenced a Class Action on Behalf of Shareholders of Regulus Therapeutics Inc. Lead Plaintiff Deadline of April 3, 2017 Business Wire
Mar-20-17 10:38AM  SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Regulus Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm Accesswire -7.84%
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of medicines that target microRNAs to treat a range of diseases in the United States and Europe. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease. RGLS4326 is an anti-miR targeting miR-17 in Phase I clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases. Regulus Therapeutics Inc. was founded in 2007 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PAPADOPOULOS STELIOSDirectorDec 28Buy1.0950,00054,570835,073Jan 02 04:12 PM
PAPADOPOULOS STELIOSDirectorDec 27Buy1.0426,40127,460785,073Dec 28 04:21 PM
PAPADOPOULOS STELIOSDirectorDec 26Buy0.9590,00085,878758,672Dec 28 04:21 PM
PAPADOPOULOS STELIOSDirectorNov 16Buy1.38300,000415,470668,672Nov 19 04:03 PM
Collier Kathryn JDirectorNov 16Buy1.417,10010,01127,596Nov 19 04:01 PM
PAPADOPOULOS STELIOSDirectorNov 15Buy1.33200,000265,080368,672Nov 19 04:03 PM
open in yahoo | open in reuters | open in google